163 related articles for article (PubMed ID: 9850939)
1. Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study.
Gutzmann H; Hadler D
J Neural Transm Suppl; 1998; 54():301-10. PubMed ID: 9850939
[TBL] [Abstract][Full Text] [Related]
2. A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease.
Weyer G; Babej-Dölle RM; Hadler D; Hofmann S; Herrmann WM
Neuropsychobiology; 1997; 36(2):73-82. PubMed ID: 9267856
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study.
Gutzmann H; Kühl KP; Hadler D; Rapp MA
Pharmacopsychiatry; 2002 Jan; 35(1):12-8. PubMed ID: 11819153
[TBL] [Abstract][Full Text] [Related]
4. Cyclandelate in the treatment of patients with mild to moderate primary degenerative dementia of the Alzheimer type or vascular dementia: experience from a placebo controlled multi-center study.
Weyer G; Eul A; Milde K; Wierich W; Herrmann WM
Pharmacopsychiatry; 2000 May; 33(3):89-97. PubMed ID: 10855459
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group.
Jann MW; Cyrus PA; Eisner LS; Margolin DI; Griffin T; Gulanski B
Clin Ther; 1999 Jan; 21(1):88-102. PubMed ID: 10090427
[TBL] [Abstract][Full Text] [Related]
6. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
De Jesus Moreno Moreno M
Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
[TBL] [Abstract][Full Text] [Related]
7. Idebenone treatment fails to slow cognitive decline in Alzheimer's disease.
Thal LJ; Grundman M; Berg J; Ernstrom K; Margolin R; Pfeiffer E; Weiner MF; Zamrini E; Thomas RG
Neurology; 2003 Dec; 61(11):1498-502. PubMed ID: 14663031
[TBL] [Abstract][Full Text] [Related]
8. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
Florian H; Meier A; Gauthier S; Lipschitz S; Lin Y; Tang Q; Othman AA; Robieson WZ; Gault LM
J Alzheimers Dis; 2016; 51(4):1237-47. PubMed ID: 26967214
[TBL] [Abstract][Full Text] [Related]
10. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
[TBL] [Abstract][Full Text] [Related]
11. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial.
Di Prospero NA; Baker A; Jeffries N; Fischbeck KH
Lancet Neurol; 2007 Oct; 6(10):878-86. PubMed ID: 17826341
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB).
Veroff AE; Bodick NC; Offen WW; Sramek JJ; Cutler NR
Alzheimer Dis Assoc Disord; 1998 Dec; 12(4):304-12. PubMed ID: 9876958
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
14. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
Rogers SL; Doody RS; Mohs RC; Friedhoff LT
Arch Intern Med; 1998 May; 158(9):1021-31. PubMed ID: 9588436
[TBL] [Abstract][Full Text] [Related]
15. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.
Raskind MA; Cyrus PA; Ruzicka BB; Gulanski BI
J Clin Psychiatry; 1999 May; 60(5):318-25. PubMed ID: 10362441
[TBL] [Abstract][Full Text] [Related]
16. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study.
Dubois B; McKeith I; Orgogozo JM; Collins O; Meulien D
Int J Geriatr Psychiatry; 1999 Nov; 14(11):973-82. PubMed ID: 10556869
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
18. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.
Bodick NC; Offen WW; Levey AI; Cutler NR; Gauthier SG; Satlin A; Shannon HE; Tollefson GD; Rasmussen K; Bymaster FP; Hurley DJ; Potter WZ; Paul SM
Arch Neurol; 1997 Apr; 54(4):465-73. PubMed ID: 9109749
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial.
Xiao S; Wang T; Ma X; Qin Y; Li X; Zhao Z; Liu X; Wang X; Xie H; Jiang Q; Sun L; Luo B; Shang L; Chen W; Bai Y; Tang M; He M; Wu L; Ma Q; Hou D; He J
Age Ageing; 2017 Sep; 46(5):767-773. PubMed ID: 28419192
[TBL] [Abstract][Full Text] [Related]
20. Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease.
Galasko D; Bell J; Mancuso JY; Kupiec JW; Sabbagh MN; van Dyck C; Thomas RG; Aisen PS;
Neurology; 2014 Apr; 82(17):1536-42. PubMed ID: 24696507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
